aspirin
Enable an AI agent to recognise aspirin, assess the identity and condition of a particular material or preparation, and determine which handling or use decisions require further evidence.
Bundle → Layer → Finding → Questions Filled
5 bundles · 9 layers · 16 findings · 24 questions
Aspirin identity and composition Establishes what evidence identifies acetylsalicylic acid and what else is present in the material.
Chemical identity
Separates evidence of acetylsalicylic acid identity from naming assumptions.
Acetylsalicylic acid identification
Record the asserted chemical identity, its supporting evidence and any conflict with related salicylate identities.
- What evidence identifies this material as acetylsalicylic acid rather than salicylic acid or another salicylate? definition
- Does the identity claim come from a product label, supplier certificate or analytical result, and can that evidence be traced to this material? provenance
Composition boundary
Determines whether aspirin is the whole material or one constituent of a preparation.
Aspirin and other constituents
Record aspirin content separately from co-active ingredients, excipients and the total mass of a dosage unit.
- Is this bulk aspirin, an aspirin-only medicine or a preparation containing additional active ingredients? boundary
- What quantity of acetylsalicylic acid is declared or measured, and is its basis a dosage unit, volume or material mass? measurement
Aspirin formulation and delivery Captures the preparation features needed to interpret how this aspirin product is supplied and used.
Dosage form and release
Identifies the exact dosage form, coating and documented release designation.
Verified release characteristics
Record formulation claims from evidence tied to the exact product rather than inferred from appearance.
- What dosage form and release designation does the verified information specify for this aspirin preparation? definition
- What evidence identifies the role of any coating, buffering constituents or other formulation features? provenance
Preparation and comparison
Connects formulation evidence to proposed manipulation or substitution.
Formulation-dependent actions
Record whether a proposed action is supported for this specific aspirin preparation and what remains unresolved.
- Do the exact product instructions support the proposed splitting, crushing, chewing, dissolving or dispersing action? action
- When comparing two aspirin preparations, which differences in strength, release designation or co-active ingredients require further review before substitution? boundary
Aspirin quality and stability Connects chemical quality, storage history and package condition to an evidenced suitability decision.
Assay and degradation evidence
Records measured aspirin content and relevant impurity evidence against a named specification.
Aspirin content and salicylic acid assessment
Keep acetylsalicylic acid assay results and any salicylic acid or other impurity results distinct, with methods and acceptance criteria.
- What do applicable tests report for acetylsalicylic acid content and salicylic acid or other specified impurities? measurement
- Which specification and analytical method support accepting or rejecting these results for the intended material role? provenance
Storage, package and disposition
Assesses actual exposure and packaging against requirements for the particular aspirin material.
Continued suitability evidence
Record batch-linked expiry or retest information, package integrity, storage excursions and the resulting disposition.
- What expiry or retest date, moisture-protection requirements and storage conditions apply to this batch or preparation? provenance
- Given observed package damage, storage excursions or missing history, what evidence supports retention, testing, quarantine or disposal? action
Aspirin use constraints and traceability Links a proposed use to authoritative product evidence, necessary clinical context and batch status.
Clinical context interface
Identifies the external patient and treatment information required before assessing a proposed administration.
Proposed use evidence
Record the proposed purpose and applicable instructions, with unresolved restrictions referred to linked clinical models.
- What proposed use is being evaluated, and which current product information or clinical guidance applies to this preparation and jurisdiction? provenance
- What information is required about age, salicylate hypersensitivity, bleeding risk, pregnancy, concurrent medicines and planned procedures before this proposed use can be assessed? boundary
Batch and supply status
Associates a physical aspirin preparation with its source and any applicable quality restriction.
Traceable product status
Record identifiers sufficient to match this aspirin material to supplier evidence and product or batch notices.
- Which manufacturer, product identifier, strength, formulation and batch identify the aspirin material under review? provenance
- Does an applicable recall, authenticity concern or quality notice require this material to be withheld from supply or use? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these kinds and varieties hold for the sense of aspirin this model covers, and on what evidence? provenance
Identifiers and schemes
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these identifiers and schemes hold for the sense of aspirin this model covers, and on what evidence? provenance
Standards and regulation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these standards and regulation hold for the sense of aspirin this model covers, and on what evidence? provenance
Real-world use
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these real-world use hold for the sense of aspirin this model covers, and on what evidence? provenance
Typical measurements
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these typical measurements hold for the sense of aspirin this model covers, and on what evidence? provenance
Failure modes and hazards
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these failure modes and hazards hold for the sense of aspirin this model covers, and on what evidence? provenance
Regional variation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these regional variation hold for the sense of aspirin this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of aspirin this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.OBJ
- Other names and narrower kinds
- acetylsalicylate, 2-(Acetyloxy)(carboxy-¹³C)benzoic acid
What it is Filled
Aspirin (acetylsalicylic acid; IUPAC 2-(acetyloxy)benzoic acid, C9H8O4) is a salicylate NSAID that covalently acetylates Ser530 of COX-1 and Ser516 of COX-2, irreversibly blocking prostaglandin and thromboxane A2 synthesis and thereby combining analgesic, antipyretic and anti-inflammatory action with a lasting antiplatelet effect that reversible NSAIDs lack.
In scope
- Identification of acetylsalicylic acid and distinction from related substances or ambiguous product names
- Aspirin content, purity and relevant impurities in a specified material or preparation
- Physical form, formulation and release characteristics of aspirin-containing preparations
- Batch, packaging, storage and condition evidence relevant to continued suitability
- Evidence and restrictions needed to evaluate a proposed handling, dispensing or administration action
Out of scope
- A person's diagnoses, treatment plan and complete medication history
- General models of pain, fever, inflammation, thrombosis or other clinical conditions
- Independent identities and effects of other active ingredients in combination products
- Manufacturing equipment, factory operations and synthesis process control
- Organisational prescribing authority, pharmacy workflows and jurisdiction-wide medicine regulation
Why it exists Filled
Enable an AI agent to recognise aspirin, assess the identity and condition of a particular material or preparation, and determine which handling or use decisions require further evidence.
Distinguishing features Filled
- Require identity evidence specifying acetylsalicylic acid; a reference to salicylates or salicylic acid alone does not establish aspirin identity.
- Check the active-ingredient declaration or analytical identification rather than recognising aspirin from a brand name, tablet colour or intended symptom.
- Distinguish bulk acetylsalicylic acid from an aspirin-containing finished preparation by its composition, dosage form and intended material role.
- Distinguish aspirin-only preparations from combination products by recording every declared active ingredient and its quantity.
- Distinguish preparations with different release characteristics using verified formulation or labelling evidence rather than assuming equal strength makes them interchangeable.
What robots and AI may and may not do Filled
Must not
- Recommend aspirin for children or teenagers with viral illness.
- Advise starting daily aspirin for heart protection or stopping it without a clinician.
- Encourage combining aspirin with anticoagulants or other painkillers without medical advice.
- Assist anyone in using aspirin to harm themselves or others.
Only with a human decision
- Starting, stopping or changing long-term aspirin therapy.
- Responding to a suspected overdose, which needs emergency care.
May
- Explain aspirin's uses and risks in general terms from reputable medical sources.
- Remind a user to take aspirin as their clinician prescribed.
- Read packaging and report strength, dose instructions and expiry.
Moral aspects Filled
- A cheap, familiar medicine can still cause serious bleeding and poisoning.
- Easy access matters for heart attack response but also for self-harm risk.
Who is affected
- Patients
- Children and teenagers
- People at risk of self-harm
Owners Filled
Steward
The person who uses it; the prescribing clinician and pharmacist answer for its supply.
Master systems
- Medicine registers of national regulators
Links to other meta-models Filled
parent
- Q28417815 - registry parent class
- Q56085456 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.aspirin
- Wikidata: Q18216 (https://www.wikidata.org/wiki/Q18216)
Direct properties required Filled
- Identity evidence: label-declared | analytically supported | conflicting | unverified
- Material role: bulk substance | manufacturing intermediate | finished medicine | laboratory reference material | unknown
- Aspirin quantity: mg per dosage unit, mg/mL, or mass fraction, with basis and uncertainty
- Assay and impurity results: percentage of stated content and named impurity concentrations, with method, date and acceptance specification
- Dosage form and release designation: verified product-specific dosage form and release designation | unknown
- Other constituents: links to co-active ingredients, excipients and coatings with their declared roles
- Storage exposure: temperature in °C, relative humidity in %, exposure duration and evidence completeness
- Packaging and suitability state: sealed | opened | damaged | quarantined | released under applicable criteria | unknown, with supporting evidence
- Applicable use evidence: links to the exact product information, jurisdiction, proposed action and relevant patient-context model
Recognition required Filled
- Small white round tablets, often scored or enteric coated, sometimes chewable or soluble.
- Packs labelled acetylsalicylic acid with the strength per tablet.
Capabilities and actions required Filled
- Resolve an aspirin name or product reference to an evidenced substance or preparation identity.
- Compare stated aspirin content and formulation across preparations while identifying unresolved substitution constraints.
- Request or interpret identity, assay and impurity testing against an applicable specification.
- Evaluate packaging and storage evidence to support retention, quarantine or disposal decisions.
- Check a proposed preparation or administration action against verified product instructions and linked clinical context.
- Trace an affected aspirin preparation to its batch and applicable recall or quality notice.
Hazards and failure modes required Filled
- Can cause stomach bleeding and increase bleeding risk with other medicines.
- Linked to Reye's syndrome in children and teenagers.
- Overdose is dangerous and needs emergency treatment.
Standards and interfaces required Filled
- European Pharmacopoeia monograph for acetylsalicylic acid, Council of Europe.
Context of use required Filled
- Aspirin is encountered in medicines used to relieve pain, reduce fever and treat inflammation.
- Its antiplatelet action also supports selected cardiovascular uses, including prevention of recurrent heart attacks or ischemic strokes.
Sources Filled
- Acetylsalicylic Acid-Primus Inter Pares in Pharmacology - Chemistry, crystal forms, hydrolysis to salicylate plus acetate, irreversible COX acetylation, ATC N02BA01, DrugBank DB00945, brand examples
- Aspirin | C9H8O4 | CID 2244 - Molecular formula, CAS 50-78-2, Wikidata Q18216, RxCUI 1191, FDA pharmacologic class (NSAID and platelet aggregation inhibitor), COX-mediated effects on pain, fever and platelets
- Acetylsalicylsäure - IUPAC name, identifiers (CAS, EC, ECHA, PubChem, DrugBank, Wikidata), ATC codes N02BA01/B01AC06/A01AD05, physical constants, German naming (ASS vs Aspirin trademark)
- aspirin (Q18216) - Canonical Wikidata item and multilingual labels for the substance
- KEGG DRUG: Aspirin - KEGG D00109/C01405, CAS, ATC mapping, JP18/USP naming, NSAID and antiplatelet classification
- Aspirin (Acetylsalicylic Acid, Ph. Eur. monograph 0309) - BP/Ph. Eur. definition as 2-(acetyloxy)benzoic acid, assay 99.5-101.0% dried substance, appearance, solubility, loss on drying, listed dosage-form monographs
- 21 CFR Part 343 - Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use - US FDA OTC monograph classes (aspirin, buffered aspirin) and USP dissolution/drug-release requirements for tablets and delayed-release forms
- Salicylic Acid (Aspirin) - StatPearls - Irreversible vs reversible COX binding, dosage forms and strengths, pharmacokinetics, Reye syndrome, adult indications including MI prophylaxis and arthritis
- Reye's syndrome - Symptoms and causes - Paediatric contraindication after viral illness, synonym trap with salicylate names, Kawasaki-disease exception
- Salicylate poisoning: An evidence-based consensus guideline for out-of-hospital management - Acute toxic dose thresholds, distinction of aspirin from other salicylates (including methyl salicylate), paediatric poisoning epidemiology after Reye warnings
- Wikipedia: Aspirin - general description of the item
Open questions
- Does an existing Vercy world model already own acetylsalicylic acid or aspirin preparations, requiring this registry entry to link to that model?
- Should this registry entry own both bulk acetylsalicylic acid and finished preparations, or represent finished medicines through linked product models?
- Which authoritative specifications and analytical methods should govern identity, assay and impurity assessment for each supported material role?
- Which markets and aspirin formulations must be covered, and what verified sources establish their preparation and substitution constraints?
- What minimum linked clinical information and review authority are required before an agent may move from recording aspirin facts to supporting a specific use decision?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q18216/spec.json